Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Zydus Worldwide DMCC has completed the acquisition of Assertio Holdings, a pharmaceuticals business in Illinois, for $23.50 per share. Assertio Holdings is a healthcare-focused pharmaceutical company with operations tied to IL acquisitions, supporting Zydus Worldwide DMCC acquisitions in the pharmaceuticals sector. The going private acquisition structure supports a strategic acquisition by consolidating ownership of Assertio Holdings acquisition targets under Zydus control. The healthcare M&A deal is categorized as a strategic acquisition and going private acquisition, with the tender offer led by Zara Merger Sub Inc. and an announced over $100M deal size.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026